Table 14.
GRADE Evidence Profile comparing infliximab vs. cyclosporine for decreasing short-term risk of colectomy, in patients hospitalized with corticosteroid-refractory acute severe ulcerative colitis
|
Infliximab compared to Cyclosporine for Hospitalized Patients with Acute Severe Ulcerative Colitis, refractory to intravenous corticosteroids | ||||||
|---|---|---|---|---|---|---|
| Outcomes | Study event rates (95% CI) | Relative effect (95% CI) | Absolute effect* | No of participants (studies) | Quality of the evidence (GRADE) | |
| Short-term colectomy | 51/193 (26.4%) | 51/192 (26.6%) | RR 1.00 (0.72 to 1.40) | 0 fewer per 1,000 (from 74 fewer to 106 more) | 285 (2 RCTs) | ⨁⨁◯◯1,2 LOW |
|
GRADE Working Group grades of evidence High quality: We are very confident that the true effect lies close to that of the estimate of the effect Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect | ||||||
1
Rated down for risk of bias (open-label)
2
Rated down for serious imprecision